Protocol Review and Monitoring System
方案审查和监控系统
基本信息
- 批准号:10320886
- 负责人:
- 金额:$ 15.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-06-01 至 2025-11-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdvocateAfrican American populationAreaBasic ScienceBiometryCancer CenterCancer Center Support GrantCancer PatientCatchment AreaClinical DataClinical ProtocolsClinical ResearchClinical Research ProtocolsClinical SciencesClinical TrialsCommittee MembersCommunitiesCommunity OutreachConsentData Management ResourcesDedicationsDisciplineDiseaseEnsureEnvironmentEvaluationFacultyFundingFutureGoalsGrowthHuman Research EthicsInfrastructureInstitutesInstitutional Review BoardsInterventionLaboratoriesLeadershipLearningMalignant NeoplasmsMentorsMinorityMonitorNorth CarolinaOnline SystemsPatientsPopulationPopulation SciencesPreparationProblem SolvingProcessProtocols documentationResearchResearch PersonnelResourcesReview CommitteeRoleSocial SciencesSystemTimeTraining and EducationUNC Lineberger Comprehensive Cancer CenterUnderrepresented MinorityUniversitiesVoiceauthoritybasecancer clinical trialclinically relevantcommunity engagementcost effectivedata managementfeasibility trialimprovedinvestigator-initiated trialmeetingsmemberrecruit
项目摘要
ABSTRACT: PROTOCOL REVIEW AND MONITORING SYSTEM
The UNC Lineberger Comprehensive Cancer Center’s Protocol Review and Monitoring System (PRMS)
facilitates internal oversight of the scientific aspects of all cancer clinical trials at the University of North
Carolina focusing on the scientific merit, priorities, and progress of clinical protocol research. The system is a
multi-step process with preliminary review by Protocol Office Disease teams (PODs) and the Resource and
Feasibility Team (RAFT) followed by formal scientific review by the Protocol Review Committee (PRC).
The PRC is chaired by Autumn McRee, MD, and meets bi-monthly to review every cancer-related clinical
protocol before it is submitted to The Office of Human Research Ethics’ Institutional Review Board (IRB). The
PRC’s primary function is to ensure the scientific quality of proposed studies. As described in Clinical Protocol
and Data Management (CPDM), PODs and RAFT review protocols for feasibility, quality, and priority before
they are submitted to the PRC. The PRC monitors study accrual and has the authority to close under-
performing trials. During 2019, the PRC reviewed 392 protocols: 156 new studies and 236 active trials for
renewal and monitoring. This represents an 8% increase over the PRMS activity at the time of our last renewal
and reflects both our growth and dedication to an effective PRMS process.
摘要:协议审查和监视系统
UNC Lineberger综合癌症中心的协议审查和监测系统(PRMS)
促进北大学所有癌症临床试验的科学方面的内部监督
卡罗来纳州专注于临床方案研究的科学优点,优先事项和进步。该系统是
协议办公室疾病团队(POD)和资源和资源的多步骤过程以及
可行性团队(RAFT),然后由协议审查委员会(PRC)进行正式科学审查。
中国由医学博士Autumn McRee主持,并每两月见面以审查与癌症有关的所有临床
在将其提交给人类研究伦理学办公室的机构审查委员会(IRB)之前。这
中国的主要功能是确保拟议研究的科学质量。如临床方案中所述
以及数据管理(CPDM),POD和RAFT审核协议,以提供可行性,质量和优先级
他们被提交给中国。中国监视研究准确性,并有权关闭未经
进行试验。在2019年期间,中国审查了392个协议:156项新研究和236个主动试验
更新和监视。这代表我们上次续签时的PRMS活动增长8%
并反映了我们对有效PRMS过程的增长和奉献精神。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AUTUMN J MCREE其他文献
AUTUMN J MCREE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AUTUMN J MCREE', 18)}}的其他基金
相似海外基金
International Conference on Cancer Health Disparities
国际癌症健康差异会议
- 批准号:
10606212 - 财政年份:2023
- 资助金额:
$ 15.17万 - 项目类别:
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)
明尼苏达大学临床与转化科学研究所 (UMN CTSI)
- 批准号:
10763967 - 财政年份:2023
- 资助金额:
$ 15.17万 - 项目类别:
1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)
1/2 改善血管疾病的结果 - 主动脉夹层 (IMPROVE-AD)
- 批准号:
10663037 - 财政年份:2023
- 资助金额:
$ 15.17万 - 项目类别:
Community to Molecular Approaches in Early Screening and Diagnosis to Promote Equitable Outcomes Through the Continuum of Care in Cancer Among Populations of African Ancestry
社区采用分子方法进行早期筛查和诊断,通过对非洲裔人群癌症的持续护理来促进公平结果
- 批准号:
10754038 - 财政年份:2023
- 资助金额:
$ 15.17万 - 项目类别:
CommunityRx – Chronic Kidney Disease (CRx-CKD)” An EMR-integrated community resources referral intervention to address structural racism and kidney health disparities in rural North Carolina
CommunityRx — 慢性肾脏病 (CRx-CKD) — 一项与 EMR 整合的社区资源转诊干预措施,旨在解决北卡罗来纳州农村地区的结构性种族主义和肾脏健康差异
- 批准号:
10743421 - 财政年份:2023
- 资助金额:
$ 15.17万 - 项目类别: